Multiple Myeloma News

Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma

Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma

Takeda will work with Memorial Sloan Kettering Cancer Center to develop CAR-T therapies for multiple myeloma.

Depth of Response Translates Into Real-World Benefit in Multiple Myeloma

Depth of Response Translates Into Real-World Benefit in Multiple Myeloma

Depth of response corresponded to overall survival and time to next treatment in real-world patients with relapsed/refractory multiple myeloma.

Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified

Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified

Investigators identify a novel role of the genes located on chr17p13 in the induction of apoptosis in multiple myeloma.

Continuous Therapy May Be Beneficial in Patients With Newly Diagnosed Multiple Myeloma

Continuous Therapy May Be Beneficial in Patients With Newly Diagnosed Multiple Myeloma

Continuous therapy appears to be the preferred treatment modality in newly diagnosed patients with multiple myeloma (MM).

CAR-T Cells Successfully Manufactured at Point of Care

CAR-T Cells Successfully Manufactured at Point of Care

CAR-T cells targeting CD19 and CD20 were successfully and reproducibly produced at the point of care within 14 days.

MCARH171, a BCMA-Targeted CAR-T in Relapsed/Refractory Multiple Myeloma: Phase 1 Readout

MCARH171, a BCMA-Targeted CAR-T in Relapsed/Refractory Multiple Myeloma: Phase 1 Readout

A readout of results from a phase 1 trial featuring MCARH171 demonstrates the potential of the human-derived BCMA-targeted CAR-T for R/R MM.

Nanjing Legend Biotech Adds More Patient Data for BCMA CAR-T

Nanjing Legend Biotech Adds More Patient Data for BCMA CAR-T

BCMA expression did not correlate with clinical response.

JCARH125 CAR-T "Highly Active" in Relapsed/Refractory Multiple Myeloma

JCARH125 CAR-T "Highly Active" in Relapsed/Refractory Multiple Myeloma

Patients saw a deepening of responses over time.

Early Findings Indicate P-BCMA-101 May Be Effective, Tolerable in R/R Multiple Myeloma

Early Findings Indicate P-BCMA-101 May Be Effective, Tolerable in R/R Multiple Myeloma

Early results of phase 1, dose-escalation trial demonstrate efficacy and safety of P-BCMA-101 CAR-T cell therapy in patients with R/R MM.

Further Investigation of AMG 420 in Relapsed/Refractory Multiple Myeloma Warranted

Further Investigation of AMG 420 in Relapsed/Refractory Multiple Myeloma Warranted

AMG 420 is an anti-B cell maturation antigen bispecific T cell engager antibody construct.

Synchronized Delivery of Proteasome and Bone Marrow Microenvironment Inhibitors in MM

Synchronized Delivery of Proteasome and Bone Marrow Microenvironment Inhibitors in MM

Restricting MM cancer cells from making contact with the bone marrow microenvironment may be achieved through the delivery of inhibitors through nanoparticles.

REGN5458 Demonstrates Antitumor Activity in Myeloma Across Various Preclinical Models

REGN5458 Demonstrates Antitumor Activity in Myeloma Across Various Preclinical Models

The investigational antibody construct exploits the power of native effector T cells, supporting antitumor activity shortly after administration.

Allogeneic BCMA-Directed CAR-T in Multiple Myeloma: Slated to Hit Phase 1 in 2019

Allogeneic BCMA-Directed CAR-T in Multiple Myeloma: Slated to Hit Phase 1 in 2019

The construct from Allogene has been engineered to avoid the serious immune-related complications linked to allogeneic transplantation.

Luspatercept Reduced RBC Transfusion Dependence in Lower-Risk Patients With Myelodysplastic Syndromes

Luspatercept Reduced RBC Transfusion Dependence in Lower-Risk Patients With Myelodysplastic Syndromes

Findings from the MEDALIST trial revealed a significant reduction in transfusion burden for patients being treated with luspatercept compared with placebo

Stringent Complete Response Criteria for Patients With Multiple Myeloma May Lack Predictive Value

Stringent Complete Response Criteria for Patients With Multiple Myeloma May Lack Predictive Value

Stringent CR criteria may not predict clinical outcomes for patients with MM.

The Role of Salvage Autologous Transplant in the Treatment of Multiple Myeloma

The Role of Salvage Autologous Transplant in the Treatment of Multiple Myeloma

Results of a comparison study, presented at ASH 2018, found that salvage HDCT followed by ASCT in patients with relapsed MM did not lead to significant difference in PFS or OS compared with continuous novel agent-based treatment.

Predicting Outcomes After Hematopoietic Stem Cell Transplant for Myelodysplastic Syndromes

Predicting Outcomes After Hematopoietic Stem Cell Transplant for Myelodysplastic Syndromes

A personalized prediction model for probability of survival in patients with MDS who undergo HCT is presented at the ASH 2018 Annual Meeting.

NKG2D CAR T Cells: No Robust Efficacy Signal in Phase 1

NKG2D CAR T Cells: No Robust Efficacy Signal in Phase 1

Phase 1 results support further development.

Daratumumab Plus Lenalidomide and Dexamethasone May Benefit Some Patients With MM

Daratumumab Plus Lenalidomide and Dexamethasone May Benefit Some Patients With MM

Patients were randomly assigned to receive either daratumumab in combination with lenalidomide (an immunomodulatory drug) and dexamethasone (a corticosteroid) or lenalidomide and dexamethasone alone.

Transplant May Be a Valid Treatment Option for Older Patients with Myeloma

Transplant May Be a Valid Treatment Option for Older Patients with Myeloma

In select older patients, transplant improved survival outcomes compared with patients who did not receive autologous stem cell transplantation.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs